Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
413 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | completed | Phase 3 | 1,449 | National Cancer Institute (NCI)NIH | 5 |
| Mar 5, 2026 |
| clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer(SOLARIS) | active not recruiting | Phase 3 | 455 | Alliance for Clinical Trials in OncologyOTHER | 2 | Mar 3, 2026 | clinicaltrials |
| NCT00003809 | Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Feb 27, 2026 | clinicaltrials |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | active not recruiting | Phase 3 | 158 | Children's Oncology GroupNETWORK | 6 | Feb 18, 2026 | clinicaltrials |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer(e3) | active not recruiting | Phase 3 | 1,939 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen(CHONQUER) | recruiting | Phase 3 | 136 | Servier Bio-Innovation LLCINDUSTRY | 17 | Feb 6, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)(SKYSCRAPER-14) | active not recruiting | Phase 3 | 687 | Hoffmann-La RocheINDUSTRY | 27 | Dec 31, 2025 | clinicaltrials |
| NCT02201992 | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | active not recruiting | Phase 3 | 166 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 19, 2025 | clinicaltrials |
| NCT02743494 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer(CheckMate 577) | completed | Phase 3 | 794 | Bristol-Myers SquibbINDUSTRY | 31 | Nov 18, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer(MONARCH 2) | active not recruiting | Phase 3 | 669 | Eli Lilly and CompanyINDUSTRY | 20 | Oct 21, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT04674683 | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma | active not recruiting | Phase 3 | 450 | HUYABIO International, LLC.INDUSTRY | 17 | Sep 24, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery(S0931) | completed | Phase 3 | 1,545 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 16, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | completed | Phase 3 | 545 | Novartis PharmaceuticalsINDUSTRY | 23 | Aug 7, 2025 | clinicaltrials |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer(PrTK03) | active not recruiting | Phase 3 | 711 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT02059499 | Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | completed | Phase 3 | 91 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 23, 2025 | clinicaltrials |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | completed | Phase 3 | 3,270 | National Cancer Institute (NCI)NIH | 4 | Jul 14, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | completed | Phase 3 | 2,014 | National Cancer Institute (NCI)NIH | 4 | Jun 12, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 | Mar 17, 2025 | clinicaltrials |
| NCT01573442 | Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment | completed | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 28, 2025 | clinicaltrials |
| NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer(VISION) | completed | Phase 3 | 861 | EndocyteINDUSTRY | 10 | Jan 13, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT01871727 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | completed | Phase 3 | 112 | Eisai Inc.INDUSTRY | 3 | Nov 13, 2024 | clinicaltrials |
| NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) | completed | Phase 3 | 203 | Inovio PharmaceuticalsINDUSTRY | 10 | Oct 17, 2024 | clinicaltrials |
| NCT04737187 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients(SUNLIGHT) | completed | Phase 3 | 492 | Taiho Oncology, Inc.INDUSTRY | 14 | Sep 24, 2024 | clinicaltrials |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions(ANCHOR) | completed | Phase 3 | 4,446 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials